MDT - Medtronic plc
| Previous Close | 85.11 |
| Open | 84.73 |
| Bid | 0.00 x 2200 |
| Ask | 87.00 x 2200 |
| Day's Range | 84.00 - 84.91 |
| 52 Week Range | 76.41 - 89.72 |
| Volume | 4,705,519 |
| Avg. Volume | 5,138,667 |
| Market Cap | 114.719B |
| Beta | 0.73 |
| PE Ratio (TTM) | 41.41 |
| EPS (TTM) | 2.04 |
| Earnings Date | May 24, 2018 |
| Forward Dividend & Yield | 1.84 (2.14%) |
| Ex-Dividend Date | 2018-03-22 |
| 1y Target Est | 91.37 |
GlobeNewswire•2 days agoMedtronic Announces 2018 Institutional Investor and Analyst Meeting and Webcast
May 18, 2018 - Medtronic plc (MDT) announced today that the company will host its biennial Institutional Investor and Analyst Meeting on Tuesday, June 5, 2018, in New York City from 8:00 a.m. to approximately 2:00 p.m. Eastern Daylight Time. The meeting will include remarks from the Medtronic executive management team on the company`s strategies for creating long-term value for its shareholders. Omar Ishrak, Medtronic chairman & chief executive officer, and Karen Parkhill, Medtronic executive vice president & chief financial officer, will give presentations on the company.
- Zacks•2 days ago
Will Medtronic (MDT) Q4 Earnings Show Growth in All Lines?
We are upbeat about solid quarterly growth on the prosperous execution of three growth strategies, namely therapy innovation, globalization and a rise in Medtronic's (MDT) economic value.
- Zacks•3 days ago
Medtronic Initiates Study on DES for Expanded Use in the US
Medtronic (MDT) focuses on boosting CSH segment. Notably, successful results from The Bifurcation Cohort study will help the company to achieve expanded FDA approval for the Resolute Onyx DES.
- GlobeNewswire•4 days ago
Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease
Medtronic Received IDE Approval from FDA to Generate Clinical Evidence with Resolute Onyx DES to Support Future Application for Expanded Indication in U.S. DUBLIN - May 16, 2018 - Medtronic plc (MDT) today announced the initiation of a clinical study in the U.S. to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions, which account for approximately 20 percent of all percutaneous coronary interventions (PCI).1 The Bifurcation Cohort, part of the RESOLUTE ONYX Post-Approval Study, will include patients with coronary artery disease (CAD) receiving the Resolute Onyx(TM) DES in sizes ranging from 2.0 mm - 5.0 mm in diameter.
- GlobeNewswire•4 days ago
Detailed Research: Economic Perspectives on Medtronic, NVIDIA, NutriSystem, AmTrust Financial Services, Kratos Defense & Security Solutions, and Envision Healthcare — What Drives Growth in Today's Competitive Landscape
NEW YORK, May 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Medtronic ...
- Motley Fool•5 days ago
Mazor Robotics Starts Its "Transition" Year Strong
Business is booming for the robotic surgery upstart.
Motley Fool•5 days agoMazor Robotics (MZOR) Q1 2018 Earnings Conference Call Transcript
MZOR earnings call for the period ending March 31, 2018.
- GlobeNewswire•5 days ago
New Analysis Shows Medtronic Cardiac Resynchronization Therapy Feature Associated with Improved Patient Survival
Real-World Data on AdaptivCRT(TM) Algorithm Presented at Heart Rhythm 2018 DUBLIN - May 15, 2018 - Medtronic plc (NYSE: MDT) announced study results showing its exclusive AdaptivCRT(TM) algorithm is associated ...
- Simply Wall St.•6 days ago
Estimating The Intrinsic Value Of Medtronic plc (NYSE:MDT)
I am going to run you through how I calculated the intrinsic value of Medtronic plc (NYSE:MDT) using the discounted cash flow (DCF) method. If you want to learn moreRead More...
- InvestorPlace•6 days ago
3 New Healthcare Stocks to Buy Right Now
As we continue to age and populations grow, demand for new and innovative healthcare solutions is only growing as well. Already preliminary data shows that MOR208 could be a better therapy than the so-called cell therapies when used in combination to cure cancer.
- GlobeNewswire•9 days ago
New Study Demonstrates Feasibility of Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System to Detect Atrial Contractions and Restore AV Synchrony
May 11, 2018 - Medtronic plc (MDT) today announced new clinical study results demonstrating that an investigational algorithm, utilizing the accelerometer signal in the Micra(TM) Transcatheter Pacing System (TPS) may restore AV synchrony, improving cardiac function in patients with sinus rhythm and atrioventricular (AV) block. The results from the MARVEL (Micra Atrial TRacking Using A Ventricular AccELerometer) feasibility study were presented today during a late-breaking session at Heart Rhythm 2018, the Heart Rhythm Society`s 39th Annual Scientific Sessions, and simultaneously published in Heart Rhythm.
- GlobeNewswire•9 days ago
Medtronic Study Confirms Feasibility of New Extravascular Approach to ICD Therapy
May 11, 2018 - Medtronic plc (MDT) today announced results from a research study demonstrating the feasibility of a novel approach to delivering pacing and defibrillation therapy in which a lead is placed under the sternum (breastbone), outside of the heart and veins. Data from the Acute Extravascular Defibrillation, Pacing and Electrogram (ASD2) study were presented during a late-breaking session at Heart Rhythm 2018, the Heart Rhythm Society`s 39th Annual Scientific Sessions.
- GlobeNewswire•10 days ago
Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2018
May 10, 2018 - Medtronic plc (MDT) announced today that it will report financial results for its fourth quarter and fiscal year 2018 on Thursday, May 24, 2018. The news release will include summary financial information for the company`s fourth quarter and fiscal year 2018, which ended on Friday, April 27, 2018. Medtronic will host a webcast at 7:00 a.m. CDT to discuss financial results for its fourth quarter and full fiscal year 2018.
- InvestorPlace•11 days ago
Intricon Corp Is a Small Company Rising Quickly
Intricon Corporation (NASDAQ: IIN) is up more than 223% in the past year. After a big move like that, you would expect a small cap like this to be overvalued. It makes small wearable medical devices smaller and better.
- GlobeNewswire•11 days ago
Data Reinforce Reduced Complications with Medtronic Micra Transcatheter Pacing System Over Traditional Pacemakers in Real-World Use
May 9, 2018 - Medtronic plc (MDT) today announced that results through 12-months from the Post-Approval Registry (PAR) for the Medtronic Micra(TM) Transcatheter Pacing System (TPS), reinforcing the high implant success rate and low complication rate seen since its U.S. approval two years ago, will be presented on Thursday, May 10 at Heart Rhythm 2018, the Heart Rhythm Society`s 39th Annual Scientific Sessions in Boston. The smallest pacemaker in the world, Micra TPS is the only leadless pacemaker approved in the U.S. New data from the PAR study showed Micra TPS in clinical practice had an implant success rate of 99.1 percent.
Markit•11 days agoSee what the IHS Markit Score report has to say about Medtronic PLC.
Medtronic PLC NYSE:MDT
- TheStreet.com•12 days ago
Here's How Medtronic Can Unlock Shareholder Value, Says Analyst
Investors on Monday, May 7, cheered the news of former JPMorgan & Co. "I think they need to buy back stock," said Evercore ISI analyst Vijay Kumar in an interview with TheStreet on Tuesday. Noting that Medtronic has cash and short-term investments totaling more than $14 billion, Kumar said repurchasing shares is a way of reassuring the market that the company finds its shares compelling at these levels.
- ACCESSWIRE•12 days ago
Today’s Research Reports on Stocks to Watch: Tetraphase Pharmaceuticals and Medtronic
NEW YORK, NY / ACCESSWIRE / May 8, 2018 / Shares of medical stocks Tetraphase Pharamceuticals and Medtronic both saw gains on Monday. Shares of Medtronic shares soared after it was announced that J.P. Morgan Chase & Co. managing director Mike Weinstein has joined the company.
Market Realist•12 days agoA Look at Abbott Laboratories’ Valuation Multiples
On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.
- Motley Fool•13 days ago
Why Teva Pharmaceutical Industries, Gramercy Property Trust, and Medtronic Jumped Today
Find out which of these stocks got a buyout bid.
Bloomberg•13 days agoMedtronic Hires JPMorgan Analyst, and Investors Rate It a ‘Buy’
For about 20 years at JPMorgan Chase & Co., Mike Weinstein covered Medtronic Plc as an analyst, raising his target price on the stock from $42 to $90. Weinstein will start immediately as a senior vice president of strategy, reporting to Chief Financial Officer Karen Parkhill, Medtronic said in a statement Monday. The company has trailed rivals, grappling with natural disasters including hurricanes and wildfires, and man-made issues such as a shortfall in production of its hottest diabetes devices.
- GlobeNewswire•13 days ago
Mike Weinstein to Join Medtronic as Senior Vice President of Strategy
May 7, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced the appointment of Mike Weinstein as Senior Vice President, Strategy. In this role, Weinstein will work with Medtronic senior management in the areas of strategy, business development, capital deployment, and shareholder value creation. Weinstein joins Medtronic from J.P. Morgan Chase & Co., where he served as a Managing Director and led the firm`s top-ranked healthcare team in equity research for more than 20 years.
- Reuters•14 days ago
BRIEF-Lifetech Scientific Corp Receives Notice From Medtronic Group That Medtronic Entered Deal
May 7 (Reuters) - Lifetech Scientific Corp: * RECEIVES NOTICE FROM MEDTRONIC GROUP THAT MEDTRONIC ENTERED DEAL WITH CHINA EVERBRIGHT LTD & ANOTHER INVESTOR * AS PER DEAL, MEDTRONIC GROUP SELLS 22.4 PERCENT ...
Market Realist•16 days agoAbbott’s Freestyle Libre CGM’s Performance, Growth Prospects
Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.
Market Realist•17 days agoABT’s Recent Stock Slump: What’s behind the Decline?
On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.
